Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
Clinician,SMA treatments,People with SMA type IV (aged 19 years and over at symptom onset),SMA treatments (nusinersen/Spinraza and risdiplam/Evrysdi),Recommended for decline,,
